141 related articles for article (PubMed ID: 6722836)
1. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Slavik M; Petty WM; Blessing JA; Creasman WT; Homesley HD
Cancer Treat Rep; 1984 May; 68(5):809-11. PubMed ID: 6722836
[No Abstract] [Full Text] [Related]
2. Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study.
Stehman FB; Blessing JA; Delgado G; Louka M
Cancer Treat Rep; 1983; 67(7-8):737-8. PubMed ID: 6871892
[No Abstract] [Full Text] [Related]
3. Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment.
Edmonson JH; Krook JE; Hilton JF; Long HJ; Cullinan SA; Everson LK; Malkasian GD
Cancer Treat Rep; 1986 Aug; 70(8):1019-20. PubMed ID: 3731147
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of tamoxifen in patients with advanced renal cell carcinoma.
Glick JH; Wein A; Torri S; Alavi J; Harris D; Brodovsky H
Cancer Treat Rep; 1980; 64(2-3):343-4. PubMed ID: 7407768
[No Abstract] [Full Text] [Related]
5. Tamoxifen in advanced and recurrent uterine sarcomas: a phase II study. Gynecological Group, Clinical Oncological Society of Australia and the Cancer Institute, Melbourne, Australia.
Cancer Treat Rep; 1986 Jun; 70(6):811-2. PubMed ID: 3731142
[No Abstract] [Full Text] [Related]
6. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.
Barakat RR; Wong G; Curtin JP; Vlamis V; Hoskins WJ
Gynecol Oncol; 1994 Nov; 55(2):164-8. PubMed ID: 7959278
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen treatment of advanced endometrial carcinoma. A phase II study.
Hald I; Salimtschik M; Mouridsen HT
Eur J Gynaecol Oncol; 1983; 4(2):83-7. PubMed ID: 6873094
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Delgado G
Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
[No Abstract] [Full Text] [Related]
9. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
[No Abstract] [Full Text] [Related]
10. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma.
Crowson MC; Dorrell A; Rolfe EB; Fielding JW
Eur J Surg Oncol; 1986 Dec; 12(4):335-6. PubMed ID: 3780986
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; DiSaia PJ; Christopherson WA
Cancer Treat Rep; 1987 Jun; 71(6):661-2. PubMed ID: 3034423
[No Abstract] [Full Text] [Related]
12. Megestrol acetate in the management of advanced endometrial carcinoma.
Wait RB
Obstet Gynecol; 1973 Jan; 41(1):129-36. PubMed ID: 4682608
[No Abstract] [Full Text] [Related]
13. Treatment of advanced endometrial adenocarcinoma with tamoxifen.
Swenerton KD
Cancer Treat Rep; 1980; 64(6-7):805-11. PubMed ID: 7427965
[No Abstract] [Full Text] [Related]
14. [Effective progestogen therapy of endometrial hyperplasia and adenocarcinoma by administration of a combined progestogen-estrogen preparation].
Miyawaki Y; Ueki M; Sugimoto O
Nihon Gan Chiryo Gakkai Shi; 1988 Oct; 23(10):2598-605. PubMed ID: 3209928
[No Abstract] [Full Text] [Related]
15. Tamoxifen: an overview of recent studies in the field of oncology.
Patterson JS; Battersby LA
Cancer Treat Rep; 1980; 64(6-7):775-8. PubMed ID: 7000349
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.
Weiselberg L; Budman D; Vinciguerra V; Schulman P; Degnan TJ
Cancer Clin Trials; 1981; 4(2):195-8. PubMed ID: 7249256
[TBL] [Abstract][Full Text] [Related]
17. [Tamoxifen. A new antiestrogen effective against uterine neoplasms].
Iversen OE; Wilhelmsen S; Segadal E
Tidsskr Nor Laegeforen; 1982 Jul; 102(19-21):1017-8. PubMed ID: 7164053
[No Abstract] [Full Text] [Related]
18. [Histological changes observed in the treatment of endometrial glandular epithelioma with lynestrenol].
Lejeune B; Wilkin P
J Gynecol Obstet Biol Reprod (Paris); 1977 Dec; 6(8):1159-69. PubMed ID: 608932
[TBL] [Abstract][Full Text] [Related]
19. Medrogestone therapy in advanced endometrial adenocarcinoma.
Waterman EA; Benson RC
Obstet Gynecol; 1967 Nov; 30(5):626-34. PubMed ID: 4167865
[No Abstract] [Full Text] [Related]
20. [An innovative protocol, cyclic hormone-chemotherapy in the treatment of high-risk localized endometrial cancer].
Audet-Lapointe P; Ayoub J; Methot Y
J Gynecol Obstet Biol Reprod (Paris); 1988; 17(6):751-5. PubMed ID: 3209835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
